Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A bladder rupture from prostate treatment was healed with catheterization and antibiotics.

This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

In a rat model, this study found that a hydrogel incorporating adipose-derived stem cells and nerve growth factor may aid in the recovery of erectile function following cavernous nerve injury.

This study found that administering Finasteride for two weeks before surgery significantly reduced intraoperative blood loss in patients undergoing monopolar TURP, with the interventional group experiencing less mean blood loss and shorter operative times compared to the control group.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

Finasteride may help prevent prostate cancer.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

Finasteride significantly reduces prostate cancer risk.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

This study found that using 5α-reductase inhibitors during active surveillance for low-risk prostate cancer reduced prostate volume by 23% and was associated with a lower progression rate.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

In this study, androgen deprivation, particularly through finasteride treatment, effectively reduced chronic bacterial prostatitis severity in rats, suggesting potential for improved treatment modalities combining finasteride and levofloxacin.

This review found that finasteride may reduce bleeding during or after TURP procedures compared to placebo, although the overall results were varied, and no long-term complications were reported.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This commentary discusses the historical understanding of castration's effects on benign prostatic hyperplasia and reports no new clinical findings.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

Dutasteride reduces DHT more effectively than finasteride.

This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.